Earnings And Revenue GrowthThe outlook now calls for substantial revenue growth in a market that is still largely untapped, making an attractive investment case.
Market OpportunityNew guidelines from the AAP now recommend exome/genome as a first-line test for kids with development delay & intellectual disability, opening a big opportunity for WGS to access general pediatricians.
Product InnovationThe ultra-rapid genome was launched, offering a fast turnaround time and competitive pricing, which may help take volumes from smaller competitors.